journal
Journals Metabolism: Clinical and Exper...

Metabolism: Clinical and Experimental

https://read.qxmd.com/read/37967646/pcsk7-a-novel-regulator-of-apolipoprotein-b-and-a-potential-target-against-non-alcoholic-fatty-liver-disease
#41
JOURNAL ARTICLE
Vatsal Sachan, Maïlys Le Dévéhat, Anna Roubtsova, Rachid Essalmani, Jean-Francois Laurendeau, Damien Garçon, Delia Susan-Resiga, Stéphanie Duval, Sahar Mikaeeli, Josée Hamelin, Alexandra Evagelidis, Michael Chong, Guillaume Paré, Elizabeta Chernetsova, Zu-Hua Gao, Isabelle Robillard, Matthieu Ruiz, Vincent Quoc-Huy Trinh, Jennifer L Estall, May Faraj, Richard C Austin, Martin Sauvageau, Annik Prat, Robert S Kiss, Nabil G Seidah
BACKGROUND: Epidemiological evidence links the proprotein convertase subtilisin/kexin 7 (PCSK7) to triglyceride (TG) metabolism. We associated the known PCSK7 gain-of-function non-coding SNP rs236918 with higher levels of plasma apolipoprotein B (apoB) and the loss-of-function coding variant p.Pro777Leu (SNP rs201598301) with lower apoB and TG. Herein, we aimed to unravel the in vivo role of liver PCSK7. METHODS: We biochemically defined the functional role of PCSK7 in lipid metabolism using hepatic cell lines and Pcsk7-/- mice...
January 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37852529/safety-and-efficacy-of-the-new-oral-small-molecule-glp-1-receptor-agonists-orforglipron-and-danuglipron-for-the-treatment-of-type-2-diabetes-and-obesity-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#42
JOURNAL ARTICLE
Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, Panagiotis Stachteas, Konstantinos I Bougioukas, Aleksandra Klisic, Nikolaos Fragakis, Manfredi Rizzo
AIMS: The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatment of type 2 diabetes mellitus (T2DM), obesity or both. METHODS: Literature search was performed through Medline (via PubMed), Cochrane Library and Scopus until August 16, 2023...
December 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38036245/the-impact-of-bariatric-surgery-on-women-with-polycystic-ovary-syndrome
#43
REVIEW
Suhaniya N S Samarasinghe, Casper Woods, Alexander Dimitri Miras
Polycystic ovary syndrome (PCOS) is the most common endocrine condition in premenopausal women and is a common cause of anovulatory subfertility. Although obesity does not form part of the diagnostic criteria, it affects a significant proportion of women with PCOS and is strongly implicated in the pathophysiology of the disease. Both PCOS and obesity are known to impact fertility in women; obesity also reduces the success of assisted reproductive technology (ART). With or without pharmacotherapy, lifestyle intervention remains the first-line treatment in women with PCOS and obesity...
November 28, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38029839/rising-global-burden-of-cancer-attributable-to-high-bmi-from-2010-to-2019
#44
JOURNAL ARTICLE
Darren Jun Hao Tan, Cheng Han Ng, Mark Muthiah, Jie Ning Yong, Douglas Chee, Margaret Teng, Zhen Yu Wong, Rebecca Wenling Zeng, Yip Han Chin, Jiong-Wei Wang, Pojsakorn Danpanichkul, Ruveena Bhavani Rajaram, Ramanuj DasGupta, Hiroyuki Suzuki, Hirokazu Takahashi, Nobuharu Tamaki, Yock Young Dan, Rashid Lui, Ajay Duseja, Mohammad Shadab Siddiqui, Khay Guan Yeoh, Arun Sanyal, Karn Wijarnpreecha, Rohit Loomba, Christos Socrates Mantzoros, Daniel Q Huang
BACKGROUND: High body mass index (BMI) is a major risk factor for cancer development, but its impact on the global burden of cancer remains unclear. METHODS: We estimated global and regional temporal trends in the burden of cancer attributable to high BMI, and the contributions of various cancer types using the framework of the Global Burden of Disease Study. RESULTS: From 2010 to 2019, there was a 35 % increase in deaths and a 34 % increase in disability-adjusted life-years from cancers attributable to high BMI...
November 27, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38016540/tm4sf19-deficiency-inhibits-osteoclast-multinucleation-and-prevents-bone-loss
#45
JOURNAL ARTICLE
Sujin Park, Jin Sun Heo, Seiya Mizuno, Min Woo Kim, Haein An, Eunji Hong, Min Gi Kang, Junil Kim, Rebecca Yun, Hyeyeon Park, Eun-Hye Noh, Min-Jung Lee, Kwiyeom Yoon, Pyunggang Kim, Minjung Son, Kyoungwha Pang, Jihee Lee, Jinah Park, Akira Ooshima, Tae-Jin Kim, Je Yeun Park, Kyung-Min Yang, Seung-Jae Myung, Hyun Bae, Kyung-Mi Lee, John Letterio, Seok Hee Park, Satoru Takahashi, Seong-Jin Kim
BACKGROUND: Multinucleation is a hallmark of osteoclast formation and has a unique ability to resorb bone matrix. During osteoclast differentiation, the cytoskeleton reorganization results in the generation of actin belts and eventual bone resorption. Tetraspanins are involved in adhesion, migration and fusion in various cells. However, its function in osteoclast is still unclear. In this study, we identified Tm4sf19, a member of the tetraspanin family, as a regulator of osteoclast function...
November 26, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38007148/plasma-metabolite-predictors-of-metabolic-syndrome-incidence-and-reversion
#46
JOURNAL ARTICLE
Zhila Semnani-Azad, Estefanía Toledo, Nancy Babio, Miguel Ruiz-Canela, Clemens Wittenbecher, Cristina Razquin, Fenglei Wang, Courtney Dennis, Amy Deik, Clary B Clish, Dolores Corella, Montserrat Fitó, Ramon Estruch, Fernando Arós, Emilio Ros, Jesús García-Gavilan, Liming Liang, Jordi Salas-Salvadó, Miguel A Martínez-González, Frank B Hu, Marta Guasch-Ferré
BACKGROUND: Metabolic Syndrome (MetS) is a progressive pathophysiological state defined by a cluster of cardiometabolic traits. However, little is known about metabolites that may be predictors of MetS incidence or reversion. Our objective was to identify plasma metabolites associated with MetS incidence or MetS reversion. METHODS: The study included 1468 participants without cardiovascular disease (CVD) but at high CVD risk at enrollment from two case-cohort studies nested within the PREvención con DIeta MEDiterránea (PREDIMED) study with baseline metabolomics data...
November 24, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38007149/intestinal-glucose-excretion-a-potential-mechanism-for-glycemic-control
#47
REVIEW
Zhigang Ke, Zongshi Lu, Qing Li, Weidong Tong
The gut has been increasingly recognized in recent years as a pivotal organ in the maintenance of glucose homeostasis. Specifically, the profound and enduring improvement in glucose metabolism achieved through metabolic surgery to modify the anatomy of the gut has prompted scholars to acknowledge that the most effective strategy for treating type 2 diabetes mellitus (T2DM) involves the gut. The mechanisms underlying the regulation of glucose metabolism by the gut encompass gut hormones, bile acids, intestinal gluconeogenesis, gut microbiota, and signaling interactions between the gut and other organs (liver, brain, adipose, etc...
November 23, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37995806/how-can-we-pharmacologically-mimic-the-mechanisms-that-make-gastric-bypass-so-effective-are-we-close-to-a-medical-bypass
#48
JOURNAL ARTICLE
Dimitrios Tsilingiris, Alexander Kokkinos
Currently, metabolic surgery (MS) constitutes the most effective means for durable weight loss of clinically meaningful magnitude, type 2 diabetes remission and resolution of non-alcoholic steatohepatitis, as well as other obesity-related comorbidities. Accumulating evidence on the mechanisms through which MS exerts its actions has highlighted the altered secretion of hormonally active peptides of intestinal origin with biological actions crucial to energy metabolism as key drivers of MS clinical effects. The initial success of glucagon-like peptide-1 (GLP-1) receptor agonists regarding weight loss and metabolic amelioration have been followed by the development of unimolecular dual and triple polyagonists, additionally exploiting the effects of glucagon and/or glucose-dependent insulinotropic polypeptide (GIP) which achieves a magnitude of weight loss approximating that of common MS operations...
November 21, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37995805/gut-derived-ammonia-contributes-to-alcohol-related-fatty-liver-development-via-facilitating-ethanol-metabolism-and-provoking-atf4-dependent-de-novo-lipogenesis-activation
#49
JOURNAL ARTICLE
Qing Song, Chueh-Lung Hwang, Yanhui Li, Jun Wang, Jooman Park, Samuel M Lee, Zhaoli Sun, Jun Sun, Yinglin Xia, Natalia Nieto, Jose Cordoba-Chacon, Yuwei Jiang, Xiaobing Dou, Zhenyuan Song
BACKGROUND & AIMS: Dysbiosis contributes to alcohol-associated liver disease (ALD); however, the precise mechanisms remain elusive. Given the critical role of the gut microbiota in ammonia production, we herein aim to investigate whether and how gut-derived ammonia contributes to ALD. METHODS: Blood samples were collected from human subjects with/without alcohol drinking. Mice were exposed to the Lieber-DeCarli isocaloric control or ethanol-containing diets with and without rifaximin (a nonabsorbable antibiotic clinically used for lowering gut ammonia production) supplementation for five weeks...
November 21, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37984732/addressing-uncertainty-about-the-role-of-structured-lifestyle-modification-for-metabolic-surgery-patients
#50
JOURNAL ARTICLE
Enda Murphy, Francis M Finucane
There is good evidence that structured lifestyle modification programmes improve health in patients with metabolic and cardiovascular disorders, but there is no specific evidence that they improve outcomes in patients undergoing metabolic or obesity surgery. Despite expert consensus guidelines stating this fact, some healthcare systems still compel patients to participate in a structured lifestyle modification programme prior to metabolic or obesity surgery. There is a well-established need for individualised multidisciplinary dietetic and physical activity care for metabolic and obesity surgery patients, and the benefits of intentional weight loss prior to surgery are well proven, but these are distinct from potentially harmful requirements for patients to undertake compulsory structured lifestyle programmes of fixed duration, frequency and intensity, which may delay surgery and reinforce obesity stigma...
November 18, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37981189/towards-personalized-genome-scale-modeling-of-inborn-errors-of-metabolism-for-systems-medicine-applications
#51
REVIEW
Almut Heinken, Sandra El Kouche, Rosa Maria Rodriguez-Guéant, Jean-Louis Guéant
Inborn errors of metabolism (IEMs) are a group of more than 1000 inherited diseases that are individually rare but have a cumulative global prevalence of 50 per 100,000 births. Recently, it has been recognized that like common diseases, patients with rare diseases can greatly vary in the manifestation and severity of symptoms. Here, we review omics-driven approaches that enable an integrated, holistic view of metabolic phenotypes in IEM patients. We focus on applications of Constraint-based Reconstruction and Analysis (COBRA), a widely used mechanistic systems biology approach, to model the effects of inherited diseases...
November 17, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37952690/ccdc92-deficiency-ameliorates-podocyte-lipotoxicity-in-diabetic-kidney-disease
#52
JOURNAL ARTICLE
Fuwen Zuo, Youzhao Wang, Xinlei Xu, Ruihao Ding, Wei Tang, Yu Sun, Xiaojie Wang, Yan Zhang, Jichao Wu, Yusheng Xie, Min Liu, Ziying Wang, Fan Yi
BACKGROUND AND AIMS: Podocyte injury is considered as the most important early event contributing to diabetic kidney disease (DKD). Recent findings provide new insights into the roles of lipids and lipid-modulating proteins as key determinants of podocyte function in health and kidney disease. CCDC92, a novel member of coiled-coil domain-containing protein family, was indicated relevant to lipid metabolism, coronary heart disease and type 2 diabetes. However, the expression pattern and role of CCDC92 in the kidney is not clear...
November 10, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37935302/transcriptional-regulation-of-amino-acid-metabolism-by-kdm2b-in-the-context-of-ncprc1-1-and-in-concert-with-myc-and-atf4
#53
JOURNAL ARTICLE
Evangelia Chavdoula, Vollter Anastas, Alessandro La Ferlita, Julian Aldana, Giuseppe Carota, Mariarita Spampinato, Burak Soysal, Ilaria Cosentini, Sameer Parashar, Anuvrat Sircar, Giovanni Nigita, Lalit Sehgal, Michael A Freitas, Philip N Tsichlis
INTRODUCTION: KDM2B encodes a JmjC domain-containing histone lysine demethylase, which functions as an oncogene in several types of tumors, including TNBC. This study was initiated to address the cancer relevance of the results of our earlier work, which had shown that overexpression of KDM2B renders mouse embryonic fibroblasts (MEFs) resistant to oxidative stress by regulating antioxidant mechanisms. METHODS: We mainly employed a multi-omics strategy consisting of RNA-Seq, quantitative TMT proteomics, Mass-spectrometry-based global metabolomics, ATAC-Seq and ChIP-seq, to explore the role of KDM2B in the resistance to oxidative stress and intermediary metabolism...
November 5, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37931873/recent-research-advances-in-metabolism-clinical-and-experimental
#54
EDITORIAL
Chrysoula Boutari, Michail Kokkorakis, Konstantinos Stefanakis, Laura Valenzuela-Vallejo, Evangelos Axarloglou, Spela Volkansek, Marlene Chakhtoura, Christos S Mantzoros
No abstract text is available yet for this article.
November 4, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37926201/the-ubiquitin-like-modifier-fat10-is-induced-in-masld-and-impairs-the-lipid-regulatory-activity-of-ppar%C3%AE
#55
JOURNAL ARTICLE
Ludivine Clavreul, Lucie Bernard, Alexia K Cotte, Nathalie Hennuyer, Cyril Bourouh, Claire Devos, Audrey Helleboid, Joel T Haas, An Verrijken, Céline Gheeraert, Bruno Derudas, Loïc Guille, Julie Chevalier, Jérôme Eeckhoute, Emmanuelle Vallez, Emilie Dorchies, Luc Van Gaal, Guillaume Lassailly, Sven Francque, Bart Staels, Réjane Paumelle
BACKGROUND AND AIMS: Peroxisome proliferator-activated receptor α (PPARα) is a key regulator of hepatic lipid metabolism and therefore a promising therapeutic target against Metabolic-dysfunction Associated Steatotic Liver Diseases (MASLD). However, its expression and activity decrease during disease progression and several of its agonists did not achieve sufficient efficiency in clinical trials with, surprisingly, a lack of steatosis improvement. Here, we identified the Human leukocyte antigen-F Adjacent Transcript 10 (FAT10) as an inhibitor of PPARα lipid metabolic activity during MASLD progression...
November 3, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37926200/statin-therapy-in-individuals-with-intermediate-cardiovascular-risk
#56
JOURNAL ARTICLE
Joongmin Kim, Hyeongsoo Kim, Sang Hyun Park, Yura Kang, Kyungdo Han, Sang-Hak Lee
BACKGROUND: As intermediate cardiovascular risk group accounts for a large part of the total population, determining appropriate cholesterol target in this population is critical. Herein, we investigated the optimal low-density lipoprotein cholesterol (LDL-C) level in individuals with intermediate cardiovascular risk after statin therapy. METHODS: This was a nationwide observational and validation cohort study (median duration of follow-up: 7.5 and 8.7 years, respectively), using data from the Korean National Health Insurance Service and a tertiary hospital database...
November 3, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37925142/interplay-of-lipid-metabolism-and-inflammation-in-podocyte-injury
#57
REVIEW
Zilv Luo, Zhaowei Chen, Jijia Hu, Guohua Ding
Podocytes are critical for maintaining permselectivity of the glomerular filtration barrier, and podocyte injury is a major cause of proteinuria in various primary and secondary glomerulopathies. Lipid dysmetabolism and inflammatory activation are the distinctive hallmarks of podocyte injury. Lipid accumulation and lipotoxicity trigger cytoskeletal rearrangement, insulin resistance, mitochondrial oxidative stress, and inflammation. Subsequently, inflammation promotes the progression of glomerulosclerosis and renal fibrosis via multiple pathways...
November 2, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37923007/can-liquid-biopsies-for-mash-help-increase-the-penetration-of-metabolic-surgery-a-narrative-review
#58
JOURNAL ARTICLE
Lidia Castagneto-Gissey, Stefan R Bornstein, Geltrude Mingrone
This narrative review highlights current evidence on non-invasive tests to predict the presence or absence as well as the severity of metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common condition characterized by fat accumulation in the liver that affects 32 % of the world population. The most severe form of MASLD is MASH in which hepatocyte ballooning and inflammation are present together with steatosis; MASH is often associated with liver fibrosis...
November 1, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37923006/sarcopenia-still-in-relative-definition-penia-and-severe-treatment-penia
#59
EDITORIAL
Stergios A Polyzos, Christos S Mantzoros
No abstract text is available yet for this article.
November 1, 2023: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/37730085/pharmacotherapy-before-and-after-bariatric-surgery
#60
REVIEW
Khaled Alabduljabbar, Carel W le Roux
Diabetes is a chronic disease that affects a vast number of individuals globally, and without optimal treatment, can lead to significant health complications. Moreover, obesity is another chronic disease with several complications, which includes type 2 diabetes. Bariatric surgery is a viable long-term choice for managing diseases such as obesity and type 2 diabetes. However, the impact of pharmacotherapy before and after surgery remains unclear. In this review, we assessed the use of pharmacotherapy in patients with obesity with or without diabetes before and after bariatric surgery, focusing on weight loss, glycemic control, and the risk of postoperative complications...
November 2023: Metabolism: Clinical and Experimental
journal
journal
23785
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.